keyword
https://read.qxmd.com/read/38660617/treatment-of-relapsed-refractory-chronic-lymphocytic-leukemia-with-zanubrutinib-after-progressing-on-other-btk-inhibitors
#41
Nkolika Nwankwo, Aswanth Reddy, Swarup Kumar, Maha Zafar
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the US, representing approximately 1.1% of all new cancers diagnosed. Most patients with CLL can be monitored without treatment, and the indicated treatment options include a CD20 monoclonal antibody with or without bruton tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and B-cell lymphoma 2 (BCL2) antagonists. We review the case of a 77-year-old female with a long-standing history of CLL predominant lymphocytosis, transfusion -independent anemia, and thrombocytopenia...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38659230/targets-and-treatments-in-primary-cns-lymphoma
#42
REVIEW
Christina von Roemeling, Andrés J M Ferreri, Carole Soussain, Han W Tun, Christian Grommes
Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma entirely localized in the central nervous system or vitreoretinal space. PCNSL generally initially responds to methotrexate-containing chemotherapy regimens, but progressive or relapsing disease is common, and the prognosis is poor for relapsed or refractory (R/R) patients. PCNSL is often characterized by activation of nuclear factor kappa B (NF-κB) due to mutations in the B-cell receptor (BCR) or toll-like receptor (TLR) pathways, as well as immune evasion...
April 24, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38657244/sequential-cd7-car-t-cell-therapy-and-allogeneic-hsct-without-gvhd-prophylaxis
#43
JOURNAL ARTICLE
Yongxian Hu, Mingming Zhang, Tingting Yang, Zhuomao Mo, Guoqing Wei, Ruirui Jing, Houli Zhao, Rongrong Chen, Cheng Zu, Tianning Gu, Pingnan Xiao, Ruimin Hong, Jingjing Feng, Shan Fu, Delin Kong, Huijun Xu, Jiazhen Cui, Simao Huang, Bin Liang, Xiaolin Yuan, Qu Cui, Hongshan Guo, Yunxian Yu, Youqin Feng, Chunxiang Jin, Jiangtao Ren, Alex H Chang, Dongrui Wang, He Huang
BACKGROUND: Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control is unclear...
April 25, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38654385/angiostrongylus-cantonensis-induces-energy-imbalance-and-dyskinesia-in-mice-by-reducing-the-expression-of-melanin-concentrating-hormone
#44
JOURNAL ARTICLE
Hui Huang, Zhongyuan Zhang, Mengdan Xing, Zihan Jin, Yue Hu, Minyu Zhou, Hang Wei, Yiwen Liang, Zhiyue Lv
BACKGROUND: Infection with Angiostrongylus cantonensis (AC) in humans or mice can lead to severe eosinophilic meningitis or encephalitis, resulting in various neurological impairments. Developing effective neuroprotective drugs to improve the quality of life in affected individuals is critical. METHODS: We conducted a Gene Ontology enrichment analysis on microarray gene expression (GSE159486) in the brains of AC-infected mice. The expression levels of melanin-concentrating hormone (MCH) were confirmed through real-time quantitative PCR (RT-qPCR) and immunofluorescence...
April 23, 2024: Parasites & Vectors
https://read.qxmd.com/read/38654358/shared-genetic-factors-and-causal-association-between-chronic-hepatitis-c-infection-and-diffuse-large-b-cell-lymphoma
#45
JOURNAL ARTICLE
Leihua Fu, Jieni Yu, Zhe Chen, Feidan Gao, Zhijian Zhang, Jiaping Fu, Weiying Feng, Pan Hong, Jing Jin
BACKGROUND: Epidemiological research and systematic meta-analyses indicate a higher risk of B-cell lymphomas in patients with chronic hepatitis C virus (HCV) compared to non-infected individuals. However, the genetic links between HCV and these lymphomas remain under-researched. METHODS: Mendelian randomization analysis was employed to explore the association between chronic hepatitis C (CHC) and B-cell lymphomas as well as chronic lymphocytic leukemia (CLL). Approximate Bayes Factor (ABF) localization analysis was conducted to find shared genetic variants that might connect CHC with B-cell lymphomas and chronic lymphocytic leukemia (CLL)...
April 23, 2024: Infectious Agents and Cancer
https://read.qxmd.com/read/38653670/clinical-significance-of-cytomegalovirus-reactivation-in-patients-with-plasma-cell-dyscrasia-who-were-treated-with-anti-cd38-monoclonal-antibody-a-retrospective-analysis-in-a-single-institution
#46
JOURNAL ARTICLE
Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, Yoko Nakanishi, Aki Kondo, Yukiyasu Kato, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Takahiro Nakashima, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida
INTRODUCTION: Anti-CD38 monoclonal antibodies (mAbs) have improved the prognosis of patients with plasma cell dyscrasia (PCD), but are also associated with increased infectious adverse events. Cytomegalovirus (CMV) is a common latent pathogen that is reactivated in immunocompromised individuals. Although CMV reactivation has mostly been reported after high-dose chemotherapy followed by stem cell transplantation in patients with PCD, cases of reactivation during anti-CD38 mAb therapy have been reported recently...
March 30, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38652865/effect-of-tyrosine-kinase-inhibitors-on-male-fertility-in-patients-with-chronic-phase-chronic-myeloid-leukemia
#47
JOURNAL ARTICLE
George Nesr, Simone Claudiani, Dragana Milojkovic, Andrew Innes, Fiona Fernando, Irene Caballes, Patience Mungozi, Richard Szydlo, Silvia Lovato, Channa Jayasena, Jane Apperley
Advancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on quality of life, including parenting children. Although tyrosine kinase inhibitors (TKI) are contraindicated in pregnancy given their teratogenic effect, their effect on male fertility is less clear with contradictory results from animal studies and case reports/series. We compared the sperm analysis parameters, as the gold-standard assessment for male fertility, of 11 patients with CP- CML before and after TKI therapy...
April 23, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38652861/challenges-in-management-of-older-patients-with-chronic-myeloid-leukemia
#48
REVIEW
Jessica M Stempel, Rory M Shallis, Rong Wong, Nikolai A Podoltsev
Tyrosine kinase inhibitors (TKIs) have significantly improved the survival of patients with chronic myeloid leukemia (CML), however, older patients are often underrepresented in pivotal trials. Approximately 20% of older adults never start treatment and face significant barriers to accomplish favorable outcomes. The treatment goal is to improve survival, prevent progression, and preserve quality of life. This is achieved through optimizing TKI doses and employing discontinuation strategies to attain treatment-free remission (TFR), a goal increasingly pursued by older patients...
April 23, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38651850/mycosis-fungoides-with-large-cell-transformation-cd30-and-b-cell-chronic-lymphocytic-leukemia
#49
JOURNAL ARTICLE
Mikela Petković, Ivana Ilić, Ružica Jurakić Tončić, Ivo Radman-Livaja, Romana Čeović
Mycosis fugnoides (MF) is an indolent cutaneous T-cell lymphoma (CTLC) and is the most common of all cutaneous lymphomas. An increased risk for developing a second primary malignancy in patients with CTCL has been described in several studies, with a range from 1.04 to 2.4 (1-4). Caucasian males are at higher risk for MF development. MF is often diagnosed at ages between 55 and 67 years, and second malignancy usually occurs 5 or 6 years after the diagnosis of MF was established (5). The most common second primary malignancies include non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung carcinoma, bladder carcinoma, and melanoma...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38651155/genetic-prediction-of-causal-association-between-serum-bilirubin-and-hematologic-malignancies-a-two-sample-mendelian-randomized-and-bioinformatics-study
#50
JOURNAL ARTICLE
Lihua Lu, Luting Luo, Xiang Li, Wanying Liu, Boheng Wu, Qing Cai, Jiazheng Li, Yan Huang, Yanxin Chen, Yongzhi Zheng, Jianda Hu
INTRODUCTION: An increasing number of cohort studies have shown a correlation between serum bilirubin and tumors, but no definitive causal relationship has been established between serum bilirubin and hematological malignancies.Therefore, the aim of the present study was to assess the causal relationship of serum bilirubin, including total bilirubin (TBIL) and direct bilirubin (DBIL), with hematological malignancies, including leukemia, lymphoma, and myeloma. METHODS: We used a genome-wide association study (GWAS) collection of TBIL, DBIL, and hematological malignancies data...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38650415/-testicular-involvement-in-pediatric-lymphoid-tumors-a-review-of-the-literature-and-a-series-of-clinical-observation
#51
JOURNAL ARTICLE
S Korneeva M, A Batmanova N, R Panferova T, T Valiev T
Lymphoid tumors with testicular involvement in childhood are rare and heterogeneous. The disease may manifest with uni- or bilateral scrotal enlargement. Comprehensive examination includes evaluation of all lymph nodes involvement, as well as ultrasound examination, magnetic resonance imaging and positron emission tomography. A diagnosis is made on basis of morphological and immunohistochemical verification. Determination of lymphoid tumor variant and stage, is recommended to perform chemotherapy according to prognostic risk group, and, in some cases, transplantation of hematopoietic stem cells is required as consolidation therapy...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38648559/cost-effectiveness-of-adding-quizartinib-to-induction-chemotherapy-for-patients-with-flt3-mutant-acute-myeloid-leukemia
#52
JOURNAL ARTICLE
Jan Philipp Bewersdorf, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
The FLT3 inhibitor quizartinib has been shown to improve overall survival when added to intensive induction chemotherapy ("7 + 3") in patients 18-75 years old with newly diagnosed AML harboring a FLT3- ITD mutation. However, the health economic implications of this approval are unknown. We evaluated the cost-effectiveness of quizartinib using a partitioned survival analysis model. One-way and probabilistic sensitivity analyses were conducted. In the base case scenario, the addition of quizartinib to 7 + 3 resulted in incremental costs of $289,932 compared with 7 + 3 alone...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38648546/a-retrospective-cohort-study-describing-chemotherapy-induced-peripheral-neuropathy-in-non-hodgkin-lymphoma-patients-treated-with-epoch%C3%A2-%C3%A2-%C3%A2-r-does-hiv-status-matter
#53
JOURNAL ARTICLE
Gretchen A McNally, Connor M Aossey, Tracy Wiczer, Loraine T Sinnott, Mark Lustberg, Robert A Baiocchi, Maryam Lustberg
The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common adverse effect of EPOCH ± R, negatively impacting long-term patient outcomes. The primary objective of this study was to determine the incidence of CIPN, stratified by HIV status, in patients treated with EPOCH ± R...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38648045/richter-syndrome-presenting-as-subcutaneous-nodules-and-a-dermal-plaque
#54
JOURNAL ARTICLE
Melissa Nickles, Samantha Hunt, Saul Turcios-Escobar, Amaara Babwah, Nisreen Mobayed, Carlos Murga-Zamalloa, Michelle Bain, John Quigley, Paul Rubinstein, Carlos Galvez
Richter syndrome (RS) describes a phenomenon in which a patient with chronic lymphocytic leukemia (CLL) develops an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Reports of cutaneous RS remain exceedingly rare. We report a 61-year-old woman with relapsed/refractory CLL presenting with several subcutaneous nodules on her arms and legs and a single dermal plaque on her abdomen. Skin biopsy revealed a diagnosis of DLBCL, ABC-type, and her clinical status rapidly deteriorated following diagnosis...
April 23, 2024: American Journal of Dermatopathology
https://read.qxmd.com/read/38646879/evaluation-of-safety-outcomes-with-transitioning-obinutuzumab-from-standard-rate-to-short-duration-infusion-in-patients-with-chronic-lymphocytic-leukemia
#55
JOURNAL ARTICLE
Caroline Fleck, Allison Karabinos, Allene Cook, Donald C Moore, Ryan Jacobs
No abstract text is available yet for this article.
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38646877/evaluating-targeted-therapies-in-older-patients-with-tp53-mutated-aml
#56
REVIEW
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Mutation of thetumor suppressor gene, TP53 ( tumor protein 53 ), occurs in up to 15% of all patients with acute myeloid leukemia (AML) and is enriched within specific clinical subsets, most notably in older adults, and including secondary AML cases arising from preceding myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), patients exposed to prior DNA-damaging, cytotoxic therapies. In all cases, these tumors have remained difficult to effectively treat with conventional therapeutic regimens. Newer approaches fortreatmentof TP53- mutated AML have shifted to interventions that maymodulate TP53 function, target downstream molecular vulnerabilities, target non-p53 dependent molecular pathways, and/or elicit immunogenic responses...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38646840/pet-ct-in-leukemia-utility-and-future-directions
#57
JOURNAL ARTICLE
Akram Al-Ibraheem, Sudqi Allouzi, Ahmed Saad Abdlkadir, Miriam Mikhail-Lette, Kamal Al-Rabi, Mohammad Ma'koseh, Peter Knoll, Zaid Abdelrhman, Omar Shahin, Malik E Juweid, Diana Paez, Egesta Lopci
2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [18F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [18F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [18F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter's transformation, and assessing the inflammatory activity associated with acute graft versus host disease...
April 22, 2024: Nuclear Medicine Communications
https://read.qxmd.com/read/38645784/recent-advancements-in-hematopoietic-stem-cell-transplantation-in-taiwan
#58
REVIEW
Chi-Cheng Li, Xavier Cheng-Hong Tsai, Wei-Han Huang, Tso-Fu Wang
Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival...
2024: Tzu chi medical journal
https://read.qxmd.com/read/38644602/recurrent-marginal-zone-lymphoma-with-bone-marrow-involvement-detected-by-%C3%A2-%C3%A2-f-fdg-pet-ct-and-biopsy-a-diagnostic-challenge
#59
JOURNAL ARTICLE
Yeong-Shin Hsiao, Shu-Chane Shen, Shih-Chuan Hsiao
BACKGROUND Marginal zone lymphoma is a low-grade, B-cell, non-Hodgkin lymphoma. Bone marrow involvement (BMI) of leukemia or lymphoma can usually be displayed in fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) with high standardized uptake values (SUV), while diffuse homogeneous ¹⁸F-FDG bone marrow uptake (BMU) in PET/CT primarily reflects hyperplastic bone marrow status. This report is of a 74-year-old man presenting with anemia and a diagnosis of recurrent marginal zone lymphoma with bone marrow involvement identified with 18F-FDG PET/CT imaging and biopsy...
April 22, 2024: American Journal of Case Reports
https://read.qxmd.com/read/38643029/soho-state-of-the-art-updates-and-next-questions-updates-on-building-your-car-t-cell-program
#60
REVIEW
Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is currently experiencing a rapid expansion of the number of patients eligible for CAR-T therapies as approvals are being seen in earlier lines of therapy. With the expanded patients eligible for these therapies, more treatment centers will be necessary to keep up with demand. Building a cellular therapy program can be a daunting task, and therefore, we present our experience with building a clinical cellular therapy program...
March 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
165366
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.